On March 2nd, Jiangsu Hengrui Pharmaceuticals (01276) spent 34.1566 million yuan to repurchase 623,000 shares of A shares.
Hengrui Medicine (01276) announced that the company spent 34.1566 million RMB on March 2, 2026 to repurchase 623,000 A-shares at a repurchase price of 54.25-55.63 RMB per share.
Jiangsu Hengrui Pharmaceuticals (01276) announced that on March 2, 2026, the company spent 34.1566 million yuan to repurchase 623,000 A shares, with a repurchase price of 54.25-55.63 yuan per share.
Related Articles
SUPER HI (09658) announces a happy profit, with expected annual net profit attributable to shareholders not less than 34 million US dollars, a year-on-year increase.
Shanxi Meineng Clean Energy Corp., Ltd. (001299.SZ) reported a net profit attributable to shareholders of 101 million yuan in 2025, a year-on-year increase of 16.10%.
DT CAPITAL(00356): Chen Zhengang appointed as independent non-executive director
SUPER HI (09658) announces a happy profit, with expected annual net profit attributable to shareholders not less than 34 million US dollars, a year-on-year increase.
Shanxi Meineng Clean Energy Corp., Ltd. (001299.SZ) reported a net profit attributable to shareholders of 101 million yuan in 2025, a year-on-year increase of 16.10%.
DT CAPITAL(00356): Chen Zhengang appointed as independent non-executive director
RECOMMEND
